TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24615745
Drug: ACH (AC
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACH (AC plus 20 mg famotidine twice-daily)
Study: 23073360
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml of MgCl2 5% solution (equivalent to 382 mg of magnesium), daily for three months
Study: 20963535
Drug: Romiplostim (0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romiplostim (0.3, 1 and 10 μg/kg intravenous; 0.1, 0.3, 1, and 2 μg/kg subcutaneous)
Study: 20963535
Drug: Weekly dosing
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly dosing of Romiplostim
Study: 20963535
Drug: Dosing intervals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing intervals ≥2 weeks of Romiplostim
Study: 11013539
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (dialogues about daily events)
Study: 8780818
Drug: Nevirapine plus
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nevirapine plus ZDV (200 mg daily for 2 weeks followed by 200 mg twice daily for 26 weeks)
Study: 21137649
Drug: Piroxicam 20
Normalized name: piroxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 20 mg IM
Study: 15704485
Drug: Cerebrolysin 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin 30 ml
Study: 2222131
Drug: Fluoxetine for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine for 10 weeks
Study: 2222131
Drug: Fluoxetine after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine after clomipramine
Study: 2222131
Drug: Clomipramine after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine after fluoxetine
Study: 29179761
Drug: Xingnao Kaiqiao
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xingnao Kaiqiao acupuncture via intradermal needling
Study: 24373419
Drug: Immediate load
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate load post-extractive implant with subepithelial connective tissue graft (grafted group)
Study: 24373419
Drug: Immediate load
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate load post-extractive implant without raising a flap (non-grafted group)
Study: 23880005
Drug: Pemetrexed (PEM)
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed (PEM) 500 mg/m² on day 1 + Carboplatin (CBP) AUC5 on day 1 for 21-day cycle
Study: 23880005
Drug: Gemcitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000 mg/m² on days 1 and 8 + Carboplatin (CBP) AUC5 on day 1 for 21-day cycle
Study: 20805741
Drug: Concurrent radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent radiation treatment
Study: 20805741
Drug: Sequential radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential radiation treatment
Study: 17035647
Drug: Olanzapine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (mean dose, 5.5 mg per day)
Study: 17035647
Drug: Quetiapine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (mean dose, 56.5 mg per day)
Study: 17035647
Drug: Risperidone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (mean dose, 1.0 mg per day)
Study: 12854452
Drug: Best proven
Normalized name: Propoven
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Best proven therapy
Study: 8723575
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa (600 IU/kg twice weekly for 3 weeks)
Study: 6341847
Drug: Intramuscular penicillin
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular penicillin G given within 60 minutes of birth
Study: 6341847
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no penicillin treatment)
Study: 6341847
Drug: Intramuscular penicillin
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular penicillin G
Study: 28640389
Drug: PF plus
Normalized name: GLYCERIN 0.25 g in 100 mL OPHTHALMIC SOLUTION/ DROPS [Oasis TEARS PF PLUS Preservative-Free Lubricant Eye]
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF plus 10 μg/m2 daily rhLTα‐Da
Study: 28640389
Drug: PF plus
Normalized name: GLYCERIN 0.25 g in 100 mL OPHTHALMIC SOLUTION/ DROPS [Oasis TEARS PF PLUS Preservative-Free Lubricant Eye]
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF plus 20 μg/m2 daily rhLTα‐Da
Study: 21790794
Drug: Topical CPS
Normalized name: CP
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical CPS (1% cantharidin, 5% podophyllotoxin, 30% salicylic acid)
Study: 15065029
Drug: Erythromycin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (3 mg/kg/dose 4 times daily)
Study: 10463321
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine infusion (bolus of 0.26 mg/kg followed by 0.65 mg/kg per hour) with oral haloperidol 5 mg
Study: 10463321
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine infusion (bolus of 0.26 mg/kg followed by 0.65 mg/kg per hour) with matched placebo
Study: 8667595
Drug: Antineoplaston A-10
Normalized name: ANTINEOPLASTON AS2-1 COMPONENT PHENYLACETIC ACID
DrugBank: Phenylacetic acid (DB09269)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antineoplaston A-10 oral formulation (14 patients)
Study: 8667595
Drug: Antineoplaston A-10
Normalized name: ANTINEOPLASTON AS2-1 COMPONENT PHENYLACETIC ACID
DrugBank: Phenylacetic acid (DB09269)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antineoplaston A-10 injectable formulation (25 patients)
Study: 8667595
Drug: Antineoplaston AS2-1
Normalized name: ANTINEOPLASTON AS2-1 COMPONENT PHENYLACETIC ACID
DrugBank: Phenylacetic acid (DB09269)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antineoplaston AS2-1 oral formulation (33 patients)
Study: 8667595
Drug: Antineoplaston AS2-1
Normalized name: ANTINEOPLASTON AS2-1 COMPONENT PHENYLACETIC ACID
DrugBank: Phenylacetic acid (DB09269)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antineoplaston AS2-1 injectable formulation (10 patients)
Study: 8667595
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with Antineoplastons
Study: 841647
Drug: BCG vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG vaccination (intrademal injection)
Study: 25283137
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of chloral hydrate (CH) for five consecutive days
Study: 25283137
Drug: 1.5 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 μg/kg of chloral hydrate (CH) for five consecutive days (environmental dose)
Study: 23348836
Drug: Topical 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5-fluorouracil
Study: 20797824
Drug: Short neoadjuvant
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short neoadjuvant hormonal therapy (4 months; Arm 1)
Study: 20797824
Drug: Long neoadjuvant
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long neoadjuvant hormonal therapy (8 months; Arm 2)
Study: 16890660
Drug: Ofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (200 mg) with bacillus Calmette‐Guerin
Study: 7970086
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (protein restriction, antihypertensive therapy)
Study: 7970086
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of treatment vs control
Study: 2451494
Drug: 0.1% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% sodium hyaluronate artificial tear preparation
Study: 2451494
Drug: 1.4% polyvinyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.4% polyvinyl alcohol and 0.5% chlorobutanol artificial tear preparation
Study: 31702992
Drug: Anodal high-voltage
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anodal high-voltage monophasic pulsed currents (HVMPC) treatment (154 μs; 100 Hz; 360 µC/sec; 1.08 C/day) for 50 minutes a day, 5 days per week, for 8 weeks.
Study: 31702992
Drug: Cathodal high-voltage
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cathodal high-voltage monophasic pulsed currents (HVMPC) treatment (154 μs; 100 Hz; 360 µC/sec; 1.08 C/day) for 50 minutes a day, 5 days per week, for 8 weeks.
Study: 31702992
Drug: Placebo (sham)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sham) treatment for 50 minutes a day, 5 days per week, for 8 weeks.
Study: 28445474
Drug: COACH program
Approvals — FDA: no, EMA: no, PMDA: no
Description: COACH program (medication reconciliation, patient counselling at discharge, communication to healthcare providers)
Study: 26007320
Drug: Condori red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Condori red grapes (500 g daily for 8 weeks)
Study: 26007320
Drug: Shahroodi white
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shahroodi white grapes (500 g daily for 8 weeks)
Study: 24001950
Drug: G-Bond (self-etching
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-Bond (self-etching adhesive)
Study: 21959045
Drug: Bevacizumab plus
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab plus mIFL (irinotecan 125 mg/m², leucovorin 20 mg/m² bolus, 5-fluorouracil 500 mg/m² weekly for four weeks every six weeks)
Study: 21959045
Drug: mIFL (irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: mIFL (irinotecan 125 mg/m², leucovorin 20 mg/m² bolus, 5-fluorouracil 500 mg/m² weekly for four weeks every six weeks)
Study: 12484510
Drug: Benazepril 5
Normalized name: benazepril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril 5 mg daily (normal dose) in patients with LVH
Study: 12484510
Drug: Benazepril 2.5
Normalized name: amlodipine-benazepril 2.5 mg-10 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril 2.5 mg daily (half dose) in patients without LVH
Study: 12484510
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of ACE inhibitor in patients with or without LVH
Study: 9771173
Drug: Fresh gas
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh gas flow rates of 1, 2 or 3 l.min‐1
Study: 383097
Drug: 3 times
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 times a day 3 mg haloperidol (3-day group)
Study: 383097
Drug: 9 mg
Normalized name: fiber 469 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mg haloperidol only in the evening (1-day group)
Study: 31392827
Drug: Betrixaban 80
Normalized name: betrixaban 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betrixaban 80 mg qd for 35 to 42 days
Study: 31493287
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg qd for 10 ± 4 days
Study: 20022809
Drug: Cisplatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (80 mg/m2 intravenously) plus Docetaxel (60 mg/m2 intravenously)
Study: 17710370
Drug: MMRV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMRV vaccine (GlaxoSmithKline Biologicals)
Study: 17710370
Drug: MMR+V (Priorix
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR+V (Priorix and Varilrix vaccines)
Study: 14713758
Drug: Phase 2
Normalized name: Premphase 28 Day Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 2 clinical trials of various agents
Study: 11781276
Drug: Budesonide 9
Normalized name: budesonide 9 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 9 mg daily for 8 weeks
Study: 2483445
Drug: Ibopamine, digitalis,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibopamine, digitalis, and diuretics
Study: 2483445
Drug: Placebo, digitalis,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, digitalis, and diuretics
Study: 28698169
Drug: Digital medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital medicine offering (DMO) for 4 weeks
Study: 28698169
Drug: Digital medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital medicine offering (DMO) for 12 weeks
Study: 28698169
Drug: Digital medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital medicine offering (DMO)
Study: 21561620
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acids (2.4 g/day of EPA and DHA for 6 weeks)
Study: 21561620
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of statins and n-3 fatty acids
Study: 18427130
Drug: Aggressive lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive lipid-lowering therapy
Study: 10325756
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily growth hormone injections (6 IU/m2/day)
Study: 10325756
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily growth hormone injections (6 IU/m2/day)
Study: 10325756
Drug: Both interventions
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both interventions (once daily and twice daily) with low dose ethinyl oestradiol (0.05 microgram/kg/day, increased to 0.10 microgram/kg/day after 2.25 years)
Study: 7489218
Drug: Epidural spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural spinal cord electrical stimulation (ESES) in addition to best medical treatment
Study: 7489218
Drug: ESES treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESES treatment
Study: 1844568
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (100 mg per day for 8 weeks)
Study: 1844568
Drug: Placebo (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (100 mg per day for 8 weeks)
Study: 6786412
Drug: 5 percent
Normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Lidocaine 5 Percent]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 percent mannitol solution orally
Study: 6786412
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 10 percent mannitol and isotonic saline
Study: 10626718
Drug: Midazolam premedication
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam premedication (2 mg im 30 min before operation)
Study: 8204811
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of nitric oxide (NO) at concentrations of 2 to 25 ppm for 6 to 10 minutes
Study: 28719485
Drug: Application of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of heat gel pack after removal of EMLA cream (treatment group)
Study: 28719485
Drug: No application
Approvals — FDA: no, EMA: no, PMDA: no
Description: No application of heat gel pack (control group)
Study: 16896965
Drug: 2/4‐mg gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2/4‐mg gum + 15‐mg patch (G/P)
Study: 16896965
Drug: 2/4‐mg lozenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2/4‐mg lozenges + 15‐mg patch (L/P)
Study: 16896965
Drug: Inhaler +
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaler + 15‐mg patch (I/P)
Study: 16896965
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg + 15‐mg patches (P/P)
Study: 16896965
Drug: Acute‐patch combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute‐patch combinations (A/P)
Study: 11889328
Drug: Intravenous salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous salbutamol (15 microg/kg as a single bolus over 10 mins)
Study: 11889328
Drug: Intravenous salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous salbutamol plus ipratropium bromide
Study: 28076829
Drug: Letrozole 2.5mg
Normalized name: LETROZOLE 2.5MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5mg once daily + Cabergoline 0.5mg/week for 12 weeks
Study: 27701629
Drug: Enhanced Conversational
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced Conversational Recast treatment (30-min session, massed condition)
Study: 27701629
Drug: Enhanced Conversational
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced Conversational Recast treatment (3 sessions of 10-min each, spaced condition)
Study: 27701629
Drug: Enhanced Conversational
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced Conversational Recast treatment (both conditions)
Study: 11944007
Drug: Gelofusine (Gel)
Normalized name: Gelofusine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelofusine (Gel)
Study: 11944007
Drug: Gel vs
Normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel vs Sal
Study: 7695302
Drug: Oral co-trimoxazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral co-trimoxazole plus topical fusidic acid
Study: 2636671
Drug: New essential
Approvals — FDA: no, EMA: no, PMDA: no
Description: New essential amino acid formulation (BS695), enriched with valine and threonine, low in phenylalanine and methionine, 3.65 g of nitrogen, i.v. three times per week for six months.
Study: 2636671
Drug: Standard amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard amino acid solution (control group), 3.65 g of nitrogen, i.v. three times per week for six months.
Study: 336670
Drug: Cyclandelate (1,600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclandelate (1,600 mg/day in fractional doses)
Study: 25108576
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (4 capsules daily, 1.01 g EPA + 0.67 g DHA)
Study: 19295240
Drug: Enzymatically modified
Normalized name: Isoquercetin enzymatically modified
DrugBank: Isoquercitrin (DB16403)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzymatically modified isoquercitrin (EMIQ) 100 mg, two capsules daily for 8 weeks
Study: 2487550
Drug: Hydrochlorothiazide/amiloride (diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide/amiloride (diuretic therapy)
Study: 28556418
Drug: KHK4083 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: KHK4083 1.0 mg/kg SC
Study: 28556418
Drug: KHK4083 0.03,
Approvals — FDA: no, EMA: no, PMDA: no
Description: KHK4083 0.03, 0.1, 0.3, 1.0, 3.0, and 10 mg/kg IV
Study: 28556418
Drug: KHK4083 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: KHK4083 (various doses)
Study: 9576302
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (low dose, < or =20 mg per day)
Study: 9576302
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (low dose)
Study: 2959438
Drug: metformin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin therapy
Study: 2959438
Drug: ultralente insulin
Normalized name: ultralente insulin, beef
Approvals — FDA: no, EMA: no, PMDA: no
Description: ultralente insulin
Study: 2959438
Drug: ultralente insulin
Normalized name: ultralente insulin, beef
Approvals — FDA: no, EMA: no, PMDA: no
Description: ultralente insulin alone
Study: 2959438
Drug: ultralente and
Normalized name: INSULIN,ULTRALENTE,HUMAN
Approvals — FDA: no, EMA: no, PMDA: no
Description: ultralente and soluble insulin
Study: 30526582
Drug: Papaya fortified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papaya fortified porridge (300 ml daily)
Study: 30526582
Drug: Albendazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (400 mg one-time dosage)
Study: 25239451
Drug: Topical propolis
Normalized name: propolis
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical propolis
Study: 19841932
Drug: Beta-alanine supplementation
Normalized name: beta-alanine
DrugBank: beta-Alanine (DB03107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-alanine supplementation (4.8 g/day for 4 weeks)
Study: 18390439
Drug: Calcium fumarate
Normalized name: calcium fumarate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium fumarate tablets
Study: 18390439
Drug: Calcium gluconate
Normalized name: Calcium Gluconate
DrugBank: Calcium gluconate (DB11126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium gluconate tablets
Study: 11811565
Drug: Raloxifene HCl
Normalized name: raloxifene HCl
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raloxifene HCl (120 mg)
Study: 11811565
Drug: Raloxifene HCl
Normalized name: raloxifene HCl
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raloxifene HCl (60 mg)
Study: 9892858
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of alcohol (BAC 0.03%)
Study: 3514193
Drug: Biosynthetic growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biosynthetic growth hormone (methionyl-hGH) administered to group I (32 children) with high ECP content
Study: 3514193
Drug: Biosynthetic growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biosynthetic growth hormone (methionyl-hGH) administered to group II (12 children) with reduced ECP content
Study: 3514193
Drug: Biosynthetic growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biosynthetic growth hormone (methionyl-hGH) administered to group III (11 children) with almost ECP-free preparations
Study: 3514193
Drug: High antibody
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High antibody titres against ECP and hGH in group I